advertisement
3.8 Pharmacology (9)
Showing records 1 to 9
Display all abstracts in classification 3.8 Pharmacology
Search within classification 3.8 Pharmacology27950 Therapeutic potential of nitric oxide modulation in ocular diseases
Drago F; Bucolo C
Drug News and Perspectives 2010; 23: 430-437
27935 Carbon monoxide and the eye: Implications for glaucoma therapy
Bucolo C; Drago F
Pharmacology and Therapeutics 2011; 130:191-201
27850 Endothelin antagonism as an active principle for glaucoma therapy
Rosenthal R; Fromm M
British Journal of Pharmacology 2011; 162: 806-816
27958 Effect of SPP 301, an endothelin antagonist, on intraocular pressure in glaucomatous monkey eyes
Wang R-F; Podos SM; Serle JB; Baltatu OC
Current Eye Research 2011; 36: 41-46
27986 Interaction of the antiglaucoma prostanoid latanoprost with the prostaglandin transporter OATP2A1
Kraft ME; Zolk O; Welge-Lussen U; Schlotzer-Schrehardt U; Kruse FE; Glaeser H; Mandery K; Konig J; Fromm MF
British Journal of Clinical Pharmacology 2009; 68: 3
27985 Neurodegeneration in glaucoma: Progression and calcium-dependent intracellular mechanisms
Crish SD; Calkins DJ
Neuroscience 2011; 176: 1-11
28019 Neuroprotective effect of PACAP against NMDA-induced retinal damage in the mouse
Endo K; Nakamachi T; Seki T; Kagami N; Wada Y; Nakamura K; Kishimoto K; Hori M; Tsuchikawa D; Shinntani N
Journal of Molecular Neuroscience 2011; 43: 22-29
28035 Synthesis and biological evaluation of 4-quinazolinones as Rho kinase inhibitors
Fang X; Chen YT; Sessions EH; Chowdhury S; Vojkovsky T; Yin Y; Pocas JR; Grant W; Schroter T; Lin L
Bioorganic and Medicinal Chemistry Letters 2011; 21:1844-1848
28222 Role of nitric oxide in the regulation of intraocular pressure: A possibility for glaucoma treatment
Vapaatalo H; Kotikoski H; Oksala O
Expert Review of Ophthalmology 2010; 5: 751-758